

Therapeutics for Women's Health: Technologies and Global Markets

Market Research Report | 2025-03-25 | 159 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

This report provides a detailed analysis of the global therapeutics for women's health technologies market, including coverage of market drivers, restraints and opportunities. It also includes analyses of this market's competitive environment and products. The report presents market estimates and forecasts for women's health therapeutics and provides market projections through 2029. For this analysis, the market is segmented by conditions related to women's health, including breast cancer, postmenopausal osteoporosis, menopause, endometriosis and polycystic ovary syndrome (PCOS), and by geographic region. The report provides company profiles of the market's leading players that feature detailed information about each company's business segments, financials, product portfolios and recent developments.

By region, the global therapeutics for women's health technologies market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes the U.K., Germany, Spain, France, Italy and the Rest of Europe; Asia-Pacific comprises China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. The rest of the World includes the Middle East and Africa, and South America. In the report's market estimates, 2021 and 2022 serve as historical years, 2023 as the base year, and data forecasts are given through 2029.

Report Includes

- 46 data tables and 63 additional tables
- An overview of the global market and technologies for women's health therapeutics
- Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Study of women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS), including their historical background, stages, symptoms, risk factors -and genetic factors, diagnosis, and treatment options
- Discussion on aging and women's health disorders, women and sexual health such as female sexual arousal disorder, female

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

orgasmic disorder and vaginismus, as well as the relationship between infertility and cancer

- Information about significant products, companies, issues and trends affecting the women's disorders and diseases industry
- Evaluation of the impact of demographic, economic and other factors that will drive demand in the market for women's health therapeutics
- Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
- Identification of the market drivers, restraints and other forces impacting the global market, as well as an evaluation of current and projected market size
- A discussion of ESG challenges and practices in the industry
- Market share analysis of the key companies and coverage of their proprietary technologies, strategic alliances, and other market strategies
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Pfizer Inc., Eli Lilly and Company, Novartis AG and Amgen Inc.

Executive Summary

Summary:

The global therapeutics for women's health technologies market is expected to grow from \$61.5 billion in 2024 and is projected to reach \$81.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2029.

In 2023, the global therapeutics for women's health technologies market was valued at \$58.3 billion. The market is forecast to grow at a CAGR of 5.7% to reach \$81.2 billion by the end of 2029.

The factors driving market growth are the growing population of older women and the rising awareness of and accessibility to healthcare and advanced therapeutic products. High treatment costs and regulatory challenges are restraining the market's growth.

In 2023, the breast cancer segment of the global therapeutics for women's health technologies held the largest share, 55.1% of the market segmented by women's health disorders, and this segment is expected to grow at a CAGR of 5.9% during the forecast period.

Table of Contents:

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Insights

Chapter 2 Market Overview

Overview

Definitions

Breast Cancer

Postmenopausal Osteoporosis

Menopause

Endometriosis

Polycystic Ovary Syndrome (PCOS)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Historical Context
Aging and Women's Health Disorders
Chapter 3 Market Dynamics
Overview
Market Drivers
Rising Population of Older Women
Increasing Awareness and Accessibility
Market Restraints
High Treatment Costs
Regulatory Challenges
Market Opportunities
Advances in Personalized Medicine
Emerging Markets
Chapter 4 Emerging Technologies
Overview
Digital Health Solutions
Advanced Fertility Technologies
Targeted Biologics and Biosimilars
Nanotechnology-Driven Drug Delivery
Gene Therapy and CRISPR
Chapter 5 Pipeline Assessment and Analysis
Overview
Women's Health Therapeutics: Key Clinical Trial Developments
Drugs in Pipeline
Overview of Osteoporosis Drug Development Pipeline
Chapter 6 Regulatory Structure
Overview of Regulations
U.S.
Drug Development and Approval Process
Types of Applications Reviewed by FDA
Canada
Food and Drugs Act (F-27)
Europe
Japan
Chapter 7 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis, by Women's Health Disorder
Breast Cancer
Postmenopausal Osteoporosis
Menopause
Endometriosis
PCOS
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Rest of the World
Chapter 8 Competitive Landscape
Overview
Market Players and Strategies
Patent Analysis
Key Developments
Chapter 9 ESG Perspective
Introduction to ESG
ESG Goals for the Pharmaceutical Sector
Focus on Energy Efficiency
Reduce Emissions and Carbon Footprint
Waste Generation and Disposal
Manufacturing, Distribution and Transportation
Social Responsibility
Governance
ESG Risk Ratings in the Pharmaceutical Industry
Concluding Remarks from BCC Research
Chapter 10 Appendix
Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
AMGEN INC.
ASAHI KASEI CORP.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
NOVO NORDISK A/S
PFIZER INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Therapeutics for Women's Health: Technologies and Global Markets

Market Research Report | 2025-03-25 | 159 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com